Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- China Approves Latuda for Schizophrenia: Sumitomo Dainippon
January 30, 2019
- Takeda to Book 38 Billion Yen Gain from Sale of Osaka HQ, Other Assets
January 29, 2019
- Ex-MHLW Bureau Chief Takeda Tapped as Senior Adviser at BCG
January 29, 2019
- Nippon Express to Set Up 4 Distribution Centers for Full-Scale Drug Logistics Biz, Aims for 15 Billion Yen Annual Sales
January 29, 2019
- Xofluza Enjoys Commanding Lead with 47% Share in October-December, MHLW Data Show
January 28, 2019
- Tamiflu Generics, Too, in Tight Supply amid Spike in Flu Patients
January 28, 2019
- Sun Pharma Poised to Raise Profile in Japan Dermatology Space, Generics and New Drugs Alike
January 25, 2019
- Takeda’s Specialty Business Unit Boots Up with Entyvio Detailing
January 25, 2019
- Shionogi, PeptiDream Join Forces for Novel Peptide Drug-Conjugate Discovery Research
January 24, 2019
- Mitsubishi Tanabe Shooting for 100 Billion Yen Sales in US/Europe, 50% Overseas Ratio
January 23, 2019
- Astellas to Transfer Dormicum to Maruishi
January 23, 2019
- Astellas, Kaketsuken Successor End Vaccine, Blood Product Pact
January 23, 2019
- SanBio’s Cell Therapy to Be Developed for Brain Bleeding Too
January 22, 2019
- Shionogi Upping Xofluza Production to Get Back to Normal before Flu Season Ends
January 22, 2019
- Mitsubishi Tanabe Eyes US as 1st Launch Market, Zeroes in on Immunology/CNS: Chief
January 22, 2019
- Janssen, Nippon Shinyaku to Copromote Prostate Cancer Treatment Apalutamide in Japan
January 22, 2019
- Shionogi Facing Xofluza Supply Crunch as Flu Season Gets into Full Swing
January 21, 2019
- Meiji Gets Thailand/Indonesia Rights to Toray’s Remitch
January 21, 2019
- Opdivo Wins Label Expansion for NSCLC in Taiwan: Ono
January 21, 2019
- Eisai’s Voluntary Redundancy Program Draws 300 Applicants in 1st Round, 3 Times More than Planned
January 21, 2019
ページ
Chugai Pharmaceutical’s Duchenne muscular dystrophy (DMD) gene therapy Elevidys has finally reached the Japanese market after months of safety reviews…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…